Analytics of the clinical implementation of pharmacogenomics testing in 12 758 individuals
Yang Wang,Fan Xiao,Yan Chen,Le-Dong Xiao,Lei-Yun Wang,Yan Zhan,Xing-Liang Xiong,Gang Zhou,Rong Liu,Dong-Sheng Ouyang,Zhi Li,Howard L. McLeod,Wei Zhang,Qing Li,Zhao-Qian Liu,Hong-Hao Zhou,Ji-Ye Yin
DOI: https://doi.org/10.1002/ctm2.586
IF: 8.554
2021-01-01
Clinical and Translational Medicine
Abstract:Dear Editor, Pharmacogenomics (PGx) testing is still not widely accepted in routinemedical practice, with one of themajor obstacles being the lack of evidence to support its clinical benefit.1,2 In the Chinese population, large-scale comprehensive analytics of clinical PGx testing are still lacking.3,4 Thus, we analysed clinical PGx testing for personalised drug treatment in 12,758 Chinese patients at Xiangya Hospital of Central South University, which is one of the first institutions to conduct clinical PGx testing in China. We aimed to evaluate both its clinical and cost benefits (costeffectiveness). Our clinical PGx testing unit was a multidisciplinary organisation integrating both the Institute of Clinical Pharmacology and a molecular testing laboratory (Figure 1A). After evaluation, 25 drug-gene pairs were selected to be tested (Table 1, Figure S1). A total of 12 758 patients were involved (from 2008 to 2020), and their basic demographic data are summarised in Table S1. They originated from at least 18 provinces, which accounted for most regions of the country (Figure 1B). Figures 1C–E show the composition of all tested genes, drug exposure, and diseases. The top three most commonly tested genes were CYP2C9, VKORC1, and CYP2C19, whichwere genotyped in 7151, 4106 and 3315 subjects, respectively. Warfarin and clopidogrel accounted for more than 10% of all drugs, and they were the most commonly prescribed to patients after PGx testing. Next, we analysed the PGx genotyping results. The details of all the tested variants are summarised in Table S2. The comparison of minor allele frequency between our results and the four other major ethnic populations is shown in Figure 1F. There were significant differences among the various populations in terms of nearly all variants. We further calculated the minor allele frequency correlation coefficients between our data and other populations. The mutations only showed good consistency in the East Asian population (Figure 1G). This result indicated that it should to evaluate clinical PGx testing in different populations because of the remarkable ethnic differences.